|
16 Feb 2020 |
Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD
|
|
13 Feb 2020 |
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma
|
|
13 Feb 2020 |
Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium
|
|
13 Feb 2020 |
Marker Therapeutics Announces Update to its Clinical Program in AML
|
|
12 Feb 2020 |
AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy
|
|
11 Feb 2020 |
LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia
|
|
11 Feb 2020 |
AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and Plato TM Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program
|
|
11 Feb 2020 |
Moderna Announces First Patient Enrolled in Phase 1/2 Study of mRNA-3704 for Methylmalonic Acidemia
|
|
10 Feb 2020 |
Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer
|
|
10 Feb 2020 |
U.S. FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma
|
|
10 Feb 2020 |
Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference
|
|
09 Feb 2020 |
Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020
|
|
06 Feb 2020 |
Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Preclinical Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
|
|
06 Feb 2020 |
CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma
|
|
06 Feb 2020 |
Calibr’s ‘switchable’ CAR-T platform for cancer moves forward with FDA clearance of Investigational New Drug application
|
|
06 Feb 2020 |
Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
|
|
04 Feb 2020 |
AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure
|
|
04 Feb 2020 |
Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
|
|
04 Feb 2020 |
HGF Gene Therapy Product Collategene AnGes Inc. initiated Phase 2b study in the U.S. in patients with lower limb ischemic ulcers
|
|
03 Feb 2020 |
Avacta and Daewoong Agree Collaboration and License Agreement with AffyXell Therapeutics
|
|
03 Feb 2020 |
Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L
|
|
02 Feb 2020 |
Alnylam Receives Positive CHMP Opinion for GIVLAARI™ (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults and Adolescents
|
|
30 Jan 2020 |
SQZ Biotech Announces First Patient Dosed in Phase 1 Trial of SQZ-PBMC-HPV for HPV+ Tumors
|
|
30 Jan 2020 |
Autolus Therapeutics Presents Encouraging Additional Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers
|
|
30 Jan 2020 |
miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease
|
